As Johnson & Johnson continues to face Risperdal lawsuit claims alleging male gynecomastia and other complications, the company must now pay millions to a whistleblower who provided the U.S. government with vital information related to the marketing of this anti-psychotic medication.
The 74-year old retired pharmacist will be paid part of a $27.5 million damage award for his role in an investigation led by the U.S. federal government, according to a report from the Chicago Tribune. The settlement, which was reached on November 4th by Johnson & Johnson, involved the company’s marketing of Risperdal and certain other medications and amounted to $2.2 billion in damages. Among other things, the U.S. Department of Justice accused the company of promoting the anti-psychotic drug, which is used in the treatment of schizophrenia and bipolar disorder to adults and adolescents, to elderly patients with dementia and children. In addition to the above conditions, research shows that Risperdal has been increasingly used in the treatment of ADHD. Meanwhile, Risperdal was not approved for pediatric uses by the U.S. Food and Drug Administration (FDA) until 2006.
The settlement agreement involved both criminal and civil charges brought against Johnson & Johnson and its subsidiary, Janssen Pharmaceuticals, Inc.
Information about this recent agreement may prove vital to the growing number of Risperdal gynecomastia lawsuit claims alleging male breast growth in men and young boys. Recently, this condition and other complications have been alleged in claims filed in the Philadelphia Court of Common Pleas, where a consolidated litigation is currently housing at least 250 lawsuits. Plaintiffs involved in these filings similarly allege male breast development, which has resulted in breast sizes as large as D-cups, in certain instances. According to claims filed against Johnson & Johnson and Janssen, the manufacturers failed to adequately warn consumers about its product’s potential to cause serious side effects.
Research published in a 2006 issue of the Journal of Clinical Psychopharmacology showed that male gynecomastia may stem from Risperdal’s potential to increase levels of prolactin, a hormone associated with breast development and lactation in females.
A Bloomberg.com report from 2012 indicates that at least five Risperdal gynecomastia lawsuits have been settled by Johnson & Johnson.
Start the process of filing a Risperdal lawsuit today by calling an attorney at Bernstein Liebhard LLP. To find out if you are eligible to receive compensation for your injuries, call .